Additionally, the omission of anthracycline in NACT backbone could have contributed to a lower response rate due to its ability to promote antitumor immunogenicity by increasing the percentage of PD-L1-positive BC cells, as demonstrated in preclinical models [94]. Here, CD274 is linked to breast cancer.